Denmark, Novo Nordisk

Novo Nordisk invests $1.2 billion in new rare disease drugs plant in Denmark
By Anna Ringstrom and Maggie Fick STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs,
Novo Nordisk invests $1.2bn in new Denmark facility
Construction has already begun on the Ozempic-producer’s new Denmark production facility and 40,000m2 warehouse.
Weight-loss drugmaker Novo Nordisk invests $1.2 bn in new factory in Denmark
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark to produce drugs against rare diseases.
Novo Nordisk differentiates itself and focuses on drugs for rare diseases: 1,4 billion euro investment
Not just drugs for obesity and diabetes. The Danish pharmaceutical giant differentiates itself in other sectors
Novo Nordisk invests $1.2 bln in new rare disease drugs plant in Denmark
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday.
Novo Nordisk to Invest $1.2 Billion in New Production Facility in Denmark
The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the rare disease area, such as haemophilia.
Novo Nordisk To Invest DKK 8.5 Bln For New Production Facility In Denmark
Healthcare company Novo Nordisk A/S (NVO) announced Monday that it plans to invest 8.5 billion Danish kroner to establish a
Novo Nordisk to invest $1.2 billion in new plant in Denmark
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday. The company said in a statement the site will include a warehouse as well as a factory.
Novo Nordisk Invests $1.2 Billion in New Factory in Denmark
Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help meet growing demand for its blockbuster drugs.
Novo Nordisk Invests DKK8.5 Bln in New Production Facility in Odense, Denmark
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...
Novo Nordisk’s Hiring Binge Leaves Danish Firms Starved of Labor
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...
STAT13d
Pharmalittle: We’re reading about a Zepbound-Wegovy faceoff, compounders slamming Novo, and more
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
JD Supra6d
Novo Nordisk Faces an Increasing Number of Lawsuits Alleging Harm Caused By Wegovy
Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both Wegovy and Ozempic) and other drug manufacturers have invested heavily ...
Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
Bloomberg L.P.13d
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first ...